Product
Name :
Qvar Inhaler
Product
Type :
Beclomethasone
Dipropionate (extra fine)
Packaging
and Product :
Inhaler 50
mcg/inhalation 200 doses, Inhaler 100 mcg/inhalation 200 doses
Manufacturer :
Aventis
Product
Classification :
Prescription
Medication
QVAR™
is the first aerosol spray capable of delivering medication to
all parts of the lung including the smallest of breathing tubes.
"Both the large and small airways in the lungs play an important
role in asthma but current inhalers fail to deliver medication
to the smallest of airways or breathing tubes," states Dr.
Kenneth Chapman, Director of the Asthma Centre at Toronto
Western Hospital. QVAR™ can ensure drug delivery to the smaller
airways, sites of inflammation that are difficult to reach and
it reverses the pattern of distribution of present inhalers by
delivering more medication to the lungs and less to the mouth
and throat. And it does all this using half the dose of most
other conventional, preventative inhalers. Dr. Chapman
continues, "QVAR's™ extra fine particles - which are about a
third the size of those of conventional inhalers are responsible
for the improved delivery of medicine to the lung and for
improvements in asthma control."
QVAR™ has been approved by Health Canada and is indicated for
the preventive management of mild, moderate or severe steroid
responsive bronchial asthma and contains the safe and effective
corticosteroid beclomethasone dipropionate (BDP).
"With the increase in asthma rates seen in recent years,
there is a growing need for delivery systems that allow patients
to receive consistent, effective and safe doses of medication
with minimal inhalation effort," says Dr. Anthony D'Urzo, a
family physician and director of the Primary Care Asthma Clinic
in Toronto. "QVAR™ certainly meets these criteria."
Dr. D'Urzo notes that studies have shown a ten-fold greater
lung deposition (the amount that actually gets into the lungs)
with CFC-free QVAR™ compared with conventional CFC-BDP inhalers.
As a result, with QVAR™, more BDP is available to the lungs to
exert a therapeutic effect while less BDP is absorbed via the
stomach. Conversely, Dr. D'Urzo adds, when a patient uses a CFC
inhaler, over 90 percent of the BDP dose is deposited in the
mouth and throat.
There are two basic types of therapies in asthma treatment:
controllers, such as QVAR™, help control inflammation and
prevent bronchospasm, while relievers lessen bronchospasm when
it occurs.
QVAR™ is available only by prescription and is a trademark of
3M™ |
